BRPI0309992B8 - método para purificar albumina de soro humano recombinante (rhsa) de uma solução - Google Patents

método para purificar albumina de soro humano recombinante (rhsa) de uma solução

Info

Publication number
BRPI0309992B8
BRPI0309992B8 BRPI0309992A BRPI0309992A BRPI0309992B8 BR PI0309992 B8 BRPI0309992 B8 BR PI0309992B8 BR PI0309992 A BRPI0309992 A BR PI0309992A BR PI0309992 A BRPI0309992 A BR PI0309992A BR PI0309992 B8 BRPI0309992 B8 BR PI0309992B8
Authority
BR
Brazil
Prior art keywords
rhsa
matrix
cation exchange
serum albumin
human serum
Prior art date
Application number
BRPI0309992A
Other languages
English (en)
Inventor
Belew Makonnen
Yan Li Mei
Zhang Wei
Original Assignee
Ge Healthcare Bio Sciences Ab
North China Pharmaceutical Group Corp
Cytiva Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Bio Sciences Ab, North China Pharmaceutical Group Corp, Cytiva Sweden Ab filed Critical Ge Healthcare Bio Sciences Ab
Publication of BRPI0309992B8 publication Critical patent/BRPI0309992B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/765Serum albumin, e.g. HSA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

MÉTODO PARA PURIFICAR ALBUMINA DE SORO HUMANO RECOMBINANTE (rHSA) DE UMA SOLUÇÃO. A presente invenção é um método de purificar albumina de soro humano recombinante (rHSA: recombinant human serum albumin) de uma matriz bimodal altamente tolerante a sal; cromatografia de interação hidrofóbica (HIC); e troca de ânions. A matriz bimodal de troca de cátions altamente tolerante a sal utilizada permite uma purificação de um sobrenadante de cultura de células diretamente, no sentido de que não é mais necessária diluição adicional do mesmo. Devido a sua alta capacidade de ligação, referida matriz bimodal de troca de cátions também permite o uso de uma quantidade menor de matriz em comparação com uma matriz de trocador de ânions convencional correspondente. Assim, a presente invenção permite economia substancial no que se refere a volumes e, conseqüentemente, a custos de operação.
BRPI0309992A 2002-05-15 2003-05-09 método para purificar albumina de soro humano recombinante (rhsa) de uma solução BRPI0309992B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201518A SE526227C2 (sv) 2002-05-15 2002-05-15 Metod för rening av rekombinant humant serumalbumin
PCT/SE2003/000766 WO2003097692A1 (en) 2002-05-15 2003-05-09 Method for albumin purification

Publications (1)

Publication Number Publication Date
BRPI0309992B8 true BRPI0309992B8 (pt) 2023-03-21

Family

ID=20287916

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0309992A BRPI0309992B8 (pt) 2002-05-15 2003-05-09 método para purificar albumina de soro humano recombinante (rhsa) de uma solução
BRPI0309992-0A BRPI0309992B1 (pt) 2002-05-15 2003-05-09 método para purificar albumina de soro humano recombinante (rhsa) de uma solução

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0309992-0A BRPI0309992B1 (pt) 2002-05-15 2003-05-09 método para purificar albumina de soro humano recombinante (rhsa) de uma solução

Country Status (13)

Country Link
US (2) US7423124B2 (pt)
EP (2) EP1504031B1 (pt)
JP (2) JP2006502098A (pt)
CN (1) CN100463921C (pt)
AT (1) ATE335006T1 (pt)
AU (2) AU2003228193B2 (pt)
BR (2) BRPI0309992B8 (pt)
CA (2) CA2483612A1 (pt)
DE (1) DE60307262T2 (pt)
ES (1) ES2268362T3 (pt)
IL (1) IL164844A (pt)
SE (1) SE526227C2 (pt)
WO (2) WO2003097692A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8802146B2 (en) * 1998-11-06 2014-08-12 Neomend, Inc. Systems, methods, and compositions for prevention of tissue adhesion
UA81791C2 (uk) * 2003-01-28 2008-02-11 Е.І. Дю Пон Дэ Нэмур Энд Компани Ціаноантраніламідні сполуки, композиція та спосіб регулювання кількості шкідників
EP1608457A1 (en) * 2003-03-12 2005-12-28 Fresenius Kabi Deutschland GmbH Use of recombinant albumin in dialysis after liver failure
EP2100904B1 (en) * 2004-04-23 2010-07-07 ConjuChem Biotechnologies Inc. Solid phase for use in a method for the purification of albumin conjugates
CN1854155B (zh) * 2005-04-29 2010-11-17 华北制药集团新药研究开发有限责任公司 一种纯化rHSA的方法
CL2008002054A1 (es) * 2007-07-17 2009-05-29 Hoffmann La Roche Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
CL2008002053A1 (es) 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
WO2009123060A1 (ja) * 2008-03-31 2009-10-08 積水メディカル株式会社 精製血清アルブミン及び免疫学的測定方法
US8753868B2 (en) * 2008-08-04 2014-06-17 General Electric Company Method and system for selective isolation of target biological molecules in a general purpose system
CN101768206B (zh) * 2008-12-31 2013-05-15 华北制药集团新药研究开发有限责任公司 一种重组人血清白蛋白的纯化方法及其应用
KR20120018827A (ko) 2009-02-20 2012-03-05 벤트리아 바이오사이언스 단백질의 조합을 함유하는 세포 배양 배지
PL2575847T5 (pl) * 2010-05-25 2022-07-18 F.Hoffmann-La Roche Ag Sposoby oczyszczania polipeptydów
CN102127164B (zh) 2010-12-20 2013-01-30 武汉禾元生物科技有限公司 一种从水稻种子中提取重组人血清白蛋白的方法
CN102532254B (zh) * 2010-12-24 2015-06-24 武汉禾元生物科技股份有限公司 一种从水稻种子中分离纯化重组人血清白蛋白的方法
US9669402B2 (en) 2012-03-08 2017-06-06 Bio-Rad Laboratories, Inc. Anionic exchange-hydrophobic mixed mode
CN103880947B (zh) 2012-12-21 2016-01-13 武汉禾元生物科技股份有限公司 一种分离纯化高纯度重组人血清白蛋白的层析方法
CN103923211A (zh) * 2014-05-08 2014-07-16 齐智 一种医药级重组人血清白蛋白的纯化方法
EP4424326A2 (en) * 2015-06-10 2024-09-04 ImmunityBio, Inc. Modified nk-92 cells for treating cancer
CN106117347A (zh) * 2015-12-09 2016-11-16 烟台大学 一种疏水层析制备高纯度藻红蛋白的方法
CN106117326A (zh) * 2015-12-09 2016-11-16 烟台大学 一种离心法结合阴离子交换层析介质制备藻红蛋白的方法
CN106146631A (zh) * 2015-12-09 2016-11-23 烟台大学 一种离心技术结合疏水层析介质制备藻红蛋白的方法
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
EP4169938A4 (en) 2020-12-08 2023-08-09 Tonghua Anrate Biopharmaceutical Co., Ltd RECOMBINANT PROTEIN PURIFICATION METHOD
CN113461804A (zh) * 2021-08-09 2021-10-01 山东健通生物科技有限公司 减少重组人血白蛋白发酵过程中色素的方法
CN113880908B (zh) * 2021-08-25 2024-05-14 北京伟德杰生物科技有限公司 纯化重组人血清白蛋白的融合蛋白的方法
CN113735962B (zh) * 2021-08-27 2023-11-10 常熟纳微生物科技有限公司 一种从猪血中纯化重组人血清白蛋白的方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093612A (en) 1975-08-04 1978-06-06 Research Corporation Selective removal of albumin from blood fluids and compositions therefore
FR2403098A1 (fr) 1977-09-19 1979-04-13 Merieux Inst Nouveau materiau capable de fixer de facon reversible des macromolecules biologiques, sa preparation et son application
DE69230273T2 (de) * 1991-07-12 2000-05-31 Dsm N.V., Heerlen Verfahren zur Reinigung von Serumalbumin
US5849874A (en) * 1991-07-12 1998-12-15 Gist-Brocades, N.V. Process for the purification of serum albumin
US5440018A (en) * 1992-05-20 1995-08-08 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
JPH07102148B2 (ja) * 1992-05-20 1995-11-08 株式会社ミドリ十字 遺伝子操作により得られるヒト血清アルブミンの製造方法、およびそれにより得られるヒト血清アルブミン含有組成物
US5521287A (en) * 1992-05-20 1996-05-28 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
CA2116385A1 (en) * 1993-02-25 1994-08-26 Akinori Sumi Human serum albumin and process for producing the same
DK0658569T3 (da) 1993-12-17 2005-02-07 Mitsubishi Pharma Corp Fremgangsmåde til affarvning af humant serumalbumin
CA2157219C (en) * 1994-08-31 2010-10-05 Munehiro Noda Process for purifying recombinant human serum albumin
JP3840674B2 (ja) * 1994-08-31 2006-11-01 三菱ウェルファーマ株式会社 遺伝子操作に由来するヒト血清アルブミンの精製方法
GB9902000D0 (en) * 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
SE0002688D0 (sv) 2000-07-17 2000-07-17 Amersham Pharm Biotech Ab Adsorption method and ligands
JP4798832B2 (ja) * 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 ヒト血清アルブミン多量体の除去方法

Also Published As

Publication number Publication date
DE60307262T2 (de) 2007-06-28
EP1504031A1 (en) 2005-02-09
US20050215765A1 (en) 2005-09-29
US20050214902A1 (en) 2005-09-29
ATE335006T1 (de) 2006-08-15
DE60307262D1 (de) 2006-09-14
SE526227C2 (sv) 2005-08-02
EP1504031B1 (en) 2006-08-02
CN100463921C (zh) 2009-02-25
JP4559216B2 (ja) 2010-10-06
US7423124B2 (en) 2008-09-09
SE0201518D0 (sv) 2002-05-15
BRPI0309992B1 (pt) 2020-12-22
CA2483612A1 (en) 2003-11-27
AU2003232704A1 (en) 2003-12-02
WO2003097693A1 (en) 2003-11-27
ES2268362T3 (es) 2007-03-16
AU2003228193B2 (en) 2009-05-07
CA2483616A1 (en) 2003-11-27
WO2003097692A1 (en) 2003-11-27
US7351801B2 (en) 2008-04-01
EP1504032A1 (en) 2005-02-09
JP2006502098A (ja) 2006-01-19
AU2003228193A1 (en) 2003-12-02
JP2006512283A (ja) 2006-04-13
IL164844A (en) 2009-09-01
IL164844A0 (en) 2005-12-18
BR0309992A (pt) 2005-03-01
CN1496993A (zh) 2004-05-19

Similar Documents

Publication Publication Date Title
BR0309992A (pt) Método para purificar albumina de soro humano recombinante (rhsa) de uma solução
BRPI0611600B8 (pt) método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit
Sun et al. Application of immobilized metal affinity chromatography in proteomics
KR101804136B1 (ko) 응고 인자 viii을 정제하는 방법
NO20064059L (no) Albumin fusjonsproteiner
RU2012130151A (ru) Промывочный раствор и способ промывки для аффинной хроматографии
CY1108046T1 (el) Μεθοδος για τον καθορισμο προπροϊνσουλινης
EA200970230A1 (ru) СПОСОБ ОЧИСТКИ Fc-СЛИТЫХ БЕЛКОВ
BRPI0713252B8 (pt) processo para a recuperação de fator de crescimento endotelial vascular (vegf) recombinante reenovelado
MX2008001865A (es) Proteinas de fusion de albumina.
BR112022022433A2 (pt) Proteínas imunomoduladoras inibitórias april e baff e métodos de uso das mesmas
HRP20020480B1 (en) Process for the purification of pharmacologically active proteins through cationic exchange chromatography
JP2018141017A5 (pt)
MEP3708A (en) Pharmaceutical compositions from beard lichen (usnea barbata) and st. john's wort (hypericum perforatum) and their use
TR200402085T4 (tr) Bazik bir amino asidi fermentasyon ortamından ayırmak için metod.
BR0316476A (pt) Composição e processo para tratar nefrite do lúpus
ATE432946T1 (de) Abtrennung von fibrinogen von plasmaproteasen
JP2016535071A5 (pt)
BR0215585A (pt) Processo de produção de fator de desenvolvimento placentário
BR112023000638A2 (pt) Aperfeiçoamentos em soluções de lavagem para a cromatografia de troca de ânions em um método de purificação de proteínas de rsv recombinantemente produzidas
MX166995B (es) Purificacion del factor de necrosis tumoral mediane membranas de politetrafluroetileno microporosas
ATE496133T1 (de) Affinitätspolypeptid zur reinigung von rekombinanten proteinen
ATE540974T1 (de) Reinigung des rekombinanten menschlichen faktors xiii
JPH01165393A (ja) 組換えヒトエリスロポエチンの精製方法
Iannucci et al. Isolation of trypsin from bovine pancreas using immobilized benzamidine and peptide CTPR ligands in expanded beds

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/05/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF